AR100815A1 - TRANSDERMAL PARASITICID FORMULATIONS, METHOD, USE - Google Patents
TRANSDERMAL PARASITICID FORMULATIONS, METHOD, USEInfo
- Publication number
- AR100815A1 AR100815A1 ARP150101866A ARP150101866A AR100815A1 AR 100815 A1 AR100815 A1 AR 100815A1 AR P150101866 A ARP150101866 A AR P150101866A AR P150101866 A ARP150101866 A AR P150101866A AR 100815 A1 AR100815 A1 AR 100815A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- transdermal
- compound
- parasiticid
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- 238000009472 formulation Methods 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 abstract 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 2
- RFEJUZJILGIRHQ-XRIOVQLTSA-N 2,3-dihydroxybutanedioic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 RFEJUZJILGIRHQ-XRIOVQLTSA-N 0.000 abstract 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 abstract 1
- 229940124339 anthelmintic agent Drugs 0.000 abstract 1
- 239000000921 anthelmintic agent Substances 0.000 abstract 1
- 239000013057 ectoparasiticide Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000002917 insecticide Substances 0.000 abstract 1
- -1 lactone compound Chemical class 0.000 abstract 1
- 229960001614 levamisole Drugs 0.000 abstract 1
- 230000000590 parasiticidal effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una formulación parasiticida transdérmica en forma de una solución que incluye una cantidad terapéuticamente efectiva del agente antihelmíntico levamisol disuelto en una solución que incluye miristato de isopropilo y D-limoneno. Reivindicación 5: La formulación de acuerdo con lo reivindicado en una cualquiera de las reivindicaciones precedentes en donde la formulación también incluye al menos un compuesto de lactona macrocíclica. Reivindicación 8: La formulación de acuerdo con lo reivindicado en una cualquiera de las reivindicaciones precedentes en donde la formulación incluye además al menos un solvente seleccionado de uno o más compuestos de dietilenglicol éter (DGE). Reivindicación 22: La formulación de acuerdo con lo reivindicado en una cualquiera de las reivindicaciones precedentes en donde la formulación incluye además al menos un compuesto activo adicional. Reivindicación 23: La formulación de acuerdo con lo reivindicado en la reivindicación 22 en donde el al menos un compuesto activo adicional es un compuesto con actividad endoparasiticida, ectoparasiticida y/o un insecticida.Claim 1: A transdermal parasiticidal formulation in the form of a solution that includes a therapeutically effective amount of the levamisole anthelmintic agent dissolved in a solution that includes isopropyl myristate and D-limonene. Claim 5: The formulation as claimed in any one of the preceding claims wherein the formulation also includes at least one macrocyclic lactone compound. Claim 8: The formulation as claimed in any one of the preceding claims wherein the formulation further includes at least one solvent selected from one or more diethylene glycol ether (DGE) compounds. Claim 22: The formulation as claimed in any one of the preceding claims wherein the formulation further includes at least one additional active compound. Claim 23: The formulation according to claim 22, wherein the at least one additional active compound is a compound with endoparasiticidal activity, ectoparasiticide and / or an insecticide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP150101866A AR100815A1 (en) | 2015-06-11 | 2015-06-11 | TRANSDERMAL PARASITICID FORMULATIONS, METHOD, USE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP150101866A AR100815A1 (en) | 2015-06-11 | 2015-06-11 | TRANSDERMAL PARASITICID FORMULATIONS, METHOD, USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100815A1 true AR100815A1 (en) | 2016-11-02 |
Family
ID=58699782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101866A AR100815A1 (en) | 2015-06-11 | 2015-06-11 | TRANSDERMAL PARASITICID FORMULATIONS, METHOD, USE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR100815A1 (en) |
-
2015
- 2015-06-11 AR ARP150101866A patent/AR100815A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000117A (en) | NEW DERIVATIVES OF QUINOLINA | |
| CO2020001244A2 (en) | Quinoline derivatives to treat helminth infections | |
| MX2016006641A (en) | NEW COMPOSITION AND METHOD OF USE TO CONTROL PATHOGENS AND PREVENT DISEASES IN SEEDS. | |
| MX2018012486A (en) | Compositions for topical application of compounds. | |
| NI201700011A (en) | 2- (MORFOLIN-4-IL) -1,7-NAPHTHYRIDINES. | |
| CO2017010065A2 (en) | Injectable extended release formulations comprising an active isoxazoline agent | |
| UY37789A (en) | NEW DERIVATIVES OF AZAQUINOLINA | |
| CR20180572A (en) | PARASITICIDE COMPOSITIONS THAT INCLUDE AN ACTIVE AGENT OF ISOXAZOLINE, ITS METHODS AND USES (Divisional 2014-0117) | |
| CL2017002164A1 (en) | Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof | |
| MX2018015709A (en) | DERIVATIVES OF AZABENCIMIDAZOL AS INHIBITORS OF PI3K BETA. | |
| CL2020000220A1 (en) | Compositions comprising amino acids for use in the treatment of diseases related to mitochondrial dysfunction. | |
| CO2019011877A2 (en) | New bicyclic pyrazole derivatives | |
| CL2019003025A1 (en) | Agricultural foaming concentrates containing a linear amide. (divisional request 201603221) | |
| MX393613B (en) | GEL COMPOSITIONS FOR TRANSDERMAL DELIVERY TO MAXIMIZE DRUG CONCENTRATIONS IN THE STRATUM CORNEUM AND SERUM, AND METHODS OF USING SAME. | |
| CO2019002246A2 (en) | Bicyclic Nitrogenous Heterocyclic Compound | |
| MX2018004304A (en) | Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors. | |
| DOP2016000007A (en) | SUBSTITUTED PIRAZOLPIRIDINS | |
| UY36460A (en) | PIRAZOLPIRIDINAMINAS | |
| CL2020000551A1 (en) | Formulation for topical use for the control and prevention of parasites in animals. | |
| CO2021016449A2 (en) | Therapeutic compositions stable in aprotic polar solvents and manufacturing methods thereof | |
| CL2020000221A1 (en) | Compositions comprising amino acids for use in the treatment of diseases related to mitochondrial dysfunction. | |
| MX2016012319A (en) | Stable veterinary anthelmintic formulations. | |
| ECSP17024551A (en) | LIMONENE: INSECTICIDE FORMULATION AND USE | |
| AR100001A1 (en) | CLOSTRIDIUM DIFFICILE SPORTS COMPOSITIONS | |
| PE20151726A1 (en) | STABLE VETERINARY FORMULATIONS OF COMBINATION OF MACROCYCLIC LACTONES AND IMIDAZOTHIAZOLES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |